Terminated PHASE2 INTERVENTIONAL 2-arm NCT02990143

The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)

Sponsor: The New York Eye & Ear Infirmary

Conditions Glaucoma

Interventions Ologen

Updated 8 times since 2017 Last updated: Mar 15, 2021 Started: Jan 15, 2014 Primary completion: Dec 15, 2017 Completion: Dec 15, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Investigator left the Institution

Other terminated trials from The New York Eye & Ear Infirmary

See all terminations from The New York Eye & Ear Infirmary

Other Glaucoma trials with similar outcome

Browse all Glaucoma trials

A PHASE2 clinical study on Glaucoma, this trial is terminated or withdrawn. The trial is conducted by The New York Eye & Ear Infirmary and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Apr 2021 — Jul 2024 [monthly]

Terminated PHASE2

Status: Unknown Status → Terminated
Jan 2021 — Apr 2021 [monthly]

Unknown Status PHASE2
Jan 2019 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Jan 2019 [monthly]

Recruiting PHASE2
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The New York Eye & Ear Infirmary

Data source: The New York Eye & Ear Infirmary

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States